GCG and type 2 diabetes mellitus: DPP-4 inhibitors, such as BI 1356 and linagliptin, are effective in the treatment of type 2 diabetes and have entered into the clinical research, as they effectively maintain blood glucose levels through degradation of incretin peptides, glucagon-like peptide 1, and glucose-dependent insulinotropic polypeptide.